Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91% Market Closed
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

Egetis Therapeutics AB (publ)
Investor Relations

Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Nicklas Westerholm
Chief Executive Officer
No Bio Available
Dr. Rob Towart
Founder
No Bio Available
Dr. Yilmaz Mahshid Ph.D.
Chief Financial Officer
No Bio Available
Dr. Katayoun Welin-Berger Ph.D.
Vice President of Operations
No Bio Available
Dr. Jacques Näsström M.B.A., MBA, Ph.D.
Chief Scientific Officer
No Bio Available
Dr. Karl Hard Ph.D.
VP and Head of Investor Relations & Communication
No Bio Available

Contacts

Address
STOCKHOLM
Stockholm
Klara Norra Kyrkogata 26
Contacts
+4686797210
www.egetis.com